Cita APA (7a ed.)
(Dec 2025). Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: A real world analysis from 15 U.S. academic centers. Blood Cancer Journal. https://doi.org/10.1038/s41408-025-01257-1
Cita Chicago Style (17a ed.)
"Outcomes in Patients with Classic Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: A Real World Analysis from 15 U.S. Academic Centers." Blood Cancer Journal Dec 2025. https://doi.org/10.1038/s41408-025-01257-1.
Cita MLA (9a ed.)
"Outcomes in Patients with Classic Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: A Real World Analysis from 15 U.S. Academic Centers." Blood Cancer Journal, Dec 2025, https://doi.org/10.1038/s41408-025-01257-1.
Precaución: Estas citas no son 100% exactas.